Udayavni Special

Oxford university Covid-19 vaccine hopes rise with strong trial results


PTI, Jul 16, 2020, 4:28 PM IST

London: Researchers at the University of Oxford believe they may have a breakthrough in their search for a COVID-19 vaccine after the team discovered that the jab could provide “double protection” against the deadly coronavirus following early-stage human trials, according to media reports in the UK.

Blood samples taken from a group of UK volunteers given a dose of the vaccine showed that it stimulated the body to produce both antibodies and “killer T-cells”, a senior source from the trial was quoted by ‘The Daily Telegraph’ as saying.

The discovery is promising because separate studies have suggested that antibodies may fade away within months while T-cells can stay in circulation for years.

However, the source cautioned that the results, while “extremely promising”, did not yet prove that the Oxford vaccine provides long-lasting immunity against the deadly virus.

“I can tell you that we now know the Oxford vaccine covers both bases: it produces both a T-cell and antibody response. It’s the combination of these two that will hopefully keep people safe. So far, so good. It’s an important moment. But we still have a long way to go,” the source said.

Another source close to the team described the presence of both antibodies and T-cells as a “double defense” against COVID-19.

‘The Lancet’ medical journal has confirmed that it would be publishing early-stage human trial data from the Oxford team on Monday.

David Carpenter, chairman of the Berkshire Research Ethics Committee, which approved the Oxford trial, said the vaccine team was “absolutely on track”.

“Nobody can put final dates… things might go wrong but the reality is that by working with a big pharma company, that vaccine could be fairly widely available around September and that is the sort of target they are working on,” he said.

The vaccine development, by the university’s Jenner Institute, is being supported by the UK government and AstraZeneca, which will support the production phase.

The pharmaceutical company said last month that phase one trials were due to finish and a phase three trial had begun which will see the vaccine given to thousands of people so it can be tested for efficacy and safety.

“The COVID-19 vaccine trial team has been working hard on assessing the safety and immunogenicity of ChAdOx1 nCoV-19, and preparing to assess vaccine efficacy,” Sarah Gilbert, professor of vaccinology at the university’s Jenner Institute who is leading the research, had said back in May.

The vaccine, named ChAdOx1 nCoV-19, is based on a weakened version of the common cold that causes infections in chimpanzees. It also contains the genetic material of the spike protein of SARS-CoV-2 – the strain of coronavirus that causes the COVID-19 illness.

The Oxford University vaccine is one of more than 100 in development as the novel coronavirus continues to spread infecting more than 13 million people and killing at least 582,000 worldwide.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Gautam Adani loses $12 billion in four days; no longer Asia’s second richest man

PM Modi launches crash course to skill, upskill over 1 lakh ‘Covid warriors’

HC to hear on June 24 Mamata’s petition challenging Suvendu’s election from Nandigram

A mix-and-match approach to COVID-19 vaccines could provide logistical and immunological benefits

MP: 4 Guards, 6 Dogs hired to protect world’s most expensive mango that sells for Rs 2.7 lakh per Kg

India records 62,480 fresh COVID-19 cases

Twitter India MD gets legal notice over Loni incident



Related Articles More

PM Modi launches crash course to skill, upskill over 1 lakh ‘Covid warriors’

A mix-and-match approach to COVID-19 vaccines could provide logistical and immunological benefits

We archived 84 million tweets to learn about the pandemic – each one is a tiny historical document

Delta variant infections doubling every 11 days in England, study finds

Anti-inflammation drug may effectively treat COVID-19 complications in children: Study

MUST WATCH

Heavy rain in Hebri

Udayavani News Bulletin 17-JUN-2021

Rain harvesting: Do you know how much water is stored for 15 minutes of rain?

Chandrakant Rao | Commercial Guava Farming in Udupi

Heavy rain continues in chikkamagaluru

Latest Additions

Outrage expressed over ‘insult’ to late actor Sanchari Vijay by Film Chamber

COVID-19: Over half crore people in Maha fully vaccinated in five months

SC refuses to cancel, postpone PG final year medical exams

Gautam Adani loses $12 billion in four days; no longer Asia’s second richest man

What is the role of animal serum in making of vaccines?

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.